Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values

Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values

Author Jones, Ronald N. Google Scholar
Fritsche, Thomas R. Google Scholar
Sader, Helio S. Google Scholar
Stilwell, Matthew G. Google Scholar
Institution JMI Labs
Tufts Univ
Universidade Federal de São Paulo (UNIFESP)
Abstract Garenoxacin, a novel des-F(6)-quinolone, was tested against 40423 pathogenic isolates associated with community-acquired respiratory tract infections (CA-RTIs). the strains included Streptococcus pneumoniae (18887), Haemophilus influenzae (15555), and Moraxella catarrhalis (5981), each isolated from a significant infection monitored by the SENTRY Antimicrobial Surveillance Program (1999-2005; North America, Latin America, and Europe). All tests were performed by reference broth microdilution methods for garenoxacin and 19 comparison agents. the garenoxacin MIC90 and percentage (%) of strains inhibited at <= 1 mu g/mL (proposed susceptible breakpoint) were S. pneumoniae (0.06 mu g/mL, > 99.9% susceptible), H. influenzae (<= 0.03 mu g/mL, > 99.9%,), and M. catarrhalis (<= 0.03 mu g/mL, 100.0%). the garenoxacin potency versus the pneumococci was 16- to 32-fold greater than levofloxacin or ciprofloxacin and 2-fold superior to moxifloxacin (MIC90, 0.12 mu g/mL). Resistances to other classes of antimicrobials did not adversely influence garenoxacin MIC results. Ciprofloxacin- or levofloxacin-resistant (MIC90, >= 4 mu g/mL) S. pneumoniae had higher garenoxacin MIC90 values (1 mu g/mL), but 90.6% to 97.5% of strains remained susceptible. Strains of all 3 monitored pathogens with mutations in the quinolone resistance determining region (QRDR) had higher garenoxacin MIC results, with >= 3 to 4 QRDR mutations required to elevate garenoxacin MIC values to 2 mu g/mL. in conclusion, garenoxacin possesses a potent activity against pneumococci, H.. influenzae, and M. catarrhalis strains worldwide, at a level significantly greater than the available tested agents in the fluoroquinolone class (ciprofloxacin, levofloxacin, and moxifloxacin). Only 13 and 4 isolates (0.07% and 0.03%) of S. pneumoniae and H. influenzae, respectively, had a garenoxacin MIC at >= 2 mu g/mL, thus, making this new respiratory antipneumococcal quinolone an attractive candidate for the therapy of coil temporary CA-RTI (bronchitis, pneumonia, and sinusitis). (c) 2007 Elsevier Inc. All rights reserved.
Keywords garenoxacin
S. pneumoniae
H. influenzae
M. catarrhalis
resistance
Language English
Date 2007-05-01
Published in Diagnostic Microbiology and Infectious Disease. New York: Elsevier B.V., v. 58, n. 1, p. 9-17, 2007.
ISSN 0732-8893 (Sherpa/Romeo, impact factor)
Publisher Elsevier B.V.
Extent 9-17
Origin http://dx.doi.org/10.1016/j.diagmicrobio.2007.01.020
Access rights Closed access
Type Article
Web of Science ID WOS:000246748000002
URI http://repositorio.unifesp.br/handle/11600/29700

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account